Mr Wallwork will also be chairing the company’s scientific advisory board where his knowledge and background in pulmonary hypertension as well as his experience in the management of R&D will be of great benefit, said Pulmo BioTech.
Mr Wallwork is currently professor of cardiothoracic surgery and director of R&D at Papworth Hospital NHS Foundation Trust, Cambridge.
Garry McCann, Pulmo BioTech’s CEO, said: “We are delighted that Mr Wallwork has agreed to join the board of Pulmo BioTech. The professor’s depth of experience and knowledge will be of great benefit to the company as we move towards Phase II human trials for our PulmoBind product candidate for the molecular imaging of the vascular system of the lungs.”